Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors

Journal of Clinical Investigation

Volumn 109, Issue 5, 2002, Pages 651-659

  Wilcox, Ryan A ^a   Flies, Dallas B ^a   Zhu, Gefeng ^a   Johnson, Aaron J ^a   Tamada, Koji ^a   Chapoval, Andrei I ^a   Strome, Scott E ^b   Pease, Larry R ^a   Chen, Lieping ^a,c  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c Tongji University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD137 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 137; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER REGRESSION; CLONAL ANERGY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; FEMALE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LUNG CARCINOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0036195860     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0214184     Document Type: Article

References (45)

1. Modulation of the immune response through 4-1BB
2. Role of 4-1BB in immune responses
3. Inducible T cell antigen 4-1BB. Analysis of expression and function
4. Costimulation of CD28- T lymphocytes by 4-1BB ligand
5. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand
6. Role of TNF receptor-associated factor 2 and p38 mitogen-activated protein kinase activation during 4-1BB-dependent immune response
7. Role of the stress kinase pathway in signaling via the T cell costimulatory receptor 4-1BB
8. NK1.1 cells express 4-1BB (CDw137) costimulatnry molecule and are required for tumor immunity, elicited by anti-4-1BB monoclonal antibodies
9. CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes
10. Signals through 4-1BB are costimulatoty to previously activated splenic T cells and inhibit activation-induced cell death
11. 4-1BB is a bona fide CD8 T cell survival signal
12. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T ceil responses
13. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus
14. 4-1BB costimulatinn is required for protective antiviral immunity after peptide vaccination
15. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
16. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine
17. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: Synergy, with the CD28 co-stimulatory pathway
18. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: Long-term remission of liver metastases in a mouse model
19. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation
20. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
21. A vaccine conjugate of 'ISCAR' immunocarrier and pepride epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants
22. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
23. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
24. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
25. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model
26. b:Vp2121-130 in the absence of endogenous CD4 help, tumor necrosis factor alpha, gamma interferon, perforin, or costimulation through CD28
27. -) to TCR/CD8 signaling in response to antigen
28. Introduction of soluble protein into the class I pathway of antigen processing and presentation
29. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway
30. Immunoglobulin fusion proteins as a tool for evaluation of T-cell costimulatory molecules
31. - T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses
32. Identification of a novel tumor-specific CTL epitope presented by RMA, EL-4, and MBL-2 lymphomas reveals their common origin
33. Immunological ignorance of silent antigens as an explanation of tumor evasion
34. Immune surveillance against a solid tumor fails because of immunological ignorance
35. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy
36. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors
37. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose
38. Immunological ignorance of an E7-induced cyrolytie T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16
39. Divergent effects of 4-1BB antibodies on antitumor immunity and on rumor-reactive T-cell generation
40. Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes
41. Papillomavirus infections - A major cause of human cancers
42. Where have all the T cells gone? Mechanisms of immune evasion by tumors
43. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
44. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice
45. - cytolytic T lymphocytes